KRON News & Events

Kronos Advanced Technologies announced the completion of its acquisition of Zyppah. In support of this strategic move, Kronos has formed a wholly owned subsidiary, Zyppah, in State of Colorado. This acquisition positions Kronos to expand into the rapidly growing sleep apnea market, integrating Zyppah's proven products with KronosMD's advanced digital health technologies to deliver enhanced, personalized solutions that could boost shareholder value. The transaction combines Zyppah established anti-snoring mouthpieces,which have generated over $55M in cumulative sales since inception, with KronosMD's upcoming remote ultrasound imaging and monitoring innovations. Upon completion of KronosMD's product development, this synergy will enable the production of custom-fitted Zyppah anti-snoring appliances, offering superior efficacy, user satisfaction, and revenue opportunities in the sleep apnea solutions sector. In connection with the acquisition, Kronos Advanced Technologies is pleased to notify its shareholders and those of the acquired Zyppah of an anticipated rights offering in the near term. This non-transferable offering will grant eligible Kronos and former Zyppah shareholders the opportunity to acquire additional Kronos common stock shares at a discounted price below market value, enabling them to preserve or expand their ownership in the merged entity. The proceeds will fund integration,product advancement, and growth in sleep apnea solutions and digital health markets, pending final terms, regulatory clearances, and adherence to securities regulations. Specifics, such as subscription pricing, ratio, and record date, will be revealed in the official announcement; shareholders should consult the prospectus for complete details.

Option delistings effective July 22nd include Radius Recycling, Inc. - Class A Common Stock (RDUS), PHX Minerals Inc. (PHX), LSEA Stock (LSEA), KRON Stock (KRON), Juniper Networks, Inc. (JNPR), INZY Stock (INZY), HARTFORD SCHRODERS COMMODITY STRATEGY ETF (HCOM), EVRI Stock (EVRI), Enstar Group Limited - Ordinary Shares (ESGR), Dada Nexus (DADA), GRANITESHARES 1X SHORT AMD DAILY ETF (AMDS), AGS Stock (AGS), RGLS Stock (RGLS), SWTX Stock (SWTX), WisdomTree Battery Value Chain and Innovation Fund (WBAT), and X Stock (X).

Kronos Bio has entered into a definitive merger agreement with Concentra Biosciences, whereby Concentra will acquire Kronos Bio for $0.57 in cash per share of Kronos Bio common stock, plus one non-tradeable contingent value right, which represents the right to receive: 50% of the net proceeds in the case of a disposition of the Company's product candidates known as KB-9558 and KB-7898 that occurs within 2 years following closing; 100% of the net proceeds in the case of a disposition of the Company's product candidates known as KB-0742, lanraplenib and entospletinib that occurs prior to closing; 100% of cost savings realized prior to closing; 80% of cost savings realized between the merger closing date and the second anniversary of the merger closing date; and 50% of cost savings realized between the second anniversary of the merger closing date and the third anniversary of the merger closing date, each pursuant to the contingent value rights agreement. Following a review process conducted with the assistance of its legal and financial advisors, the Kronos Bio Board of Directors has determined that the acquisition by Concentra is in the best interests of all Kronos Bio shareholders and has approved the Merger Agreement and related transactions. Pursuant and subject to the terms of the Merger Agreement, a wholly owned subsidiary of Concentra will commence a tender offer by May 15, 2025 to acquire all outstanding shares of Kronos Bio Common Stock. Closing of the Offer is subject to certain conditions, including the tender of Kronos Bio Common Stock representing at least a majority of the total number of outstanding shares, the availability of at least $40.0 million of cash at closing, and other customary closing conditions. Kronos Bio officers, directors and their respective affiliates holding approximately 27% of Kronos Bio Common Stock have signed tender and support agreements under which such parties have agreed to tender their shares in the Offer and support the merger transaction. The merger transaction is expected to close mid-2025.

Reports Q4 revenue $ $2.27M, vs. $2.29M last year. Cash, cash equivalents and investments: Cash, cash equivalents and investments as of December 31 were $112.4M.